open access
Thromboprophylaxis in patients with Covid-19
Affiliations- National Tuberculosis and Lung Diseases Research Institute Warsaw Poland, Plocka 26, 01-138 Warsaw, Poland
- Masovian Cancer Hospital, Wieliszew, Poland, Kościelna 61, 05-135 Wieliszew, Poland
open access
Abstract
Abstract For two years, the entire world has been grappling with the new challenge that is the Covid-19 pandemic. In December 2019 in China’s largest province, Wuhan, Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2), was detected in a patient with severe respiratory failure. Shortly after, infections were detected in all regions of the world. So far, 265 million infections have been confirmed around the world, and 5.2 million of those infected have died due to Covid-19. Infection with SARS-CoV-2 is associated with an increased risk of cardiovascular complications, especially thromboembolic complications. Low-molecular-weight-heparin presents a basic form of prophylaxis against thromboembolic complications in individuals who are ill with COVID-19. Controversy still exists regarding the optimal dose of LMWH depending on disease severity, this problem requires further randomised trials.
Abstract
Abstract For two years, the entire world has been grappling with the new challenge that is the Covid-19 pandemic. In December 2019 in China’s largest province, Wuhan, Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2), was detected in a patient with severe respiratory failure. Shortly after, infections were detected in all regions of the world. So far, 265 million infections have been confirmed around the world, and 5.2 million of those infected have died due to Covid-19. Infection with SARS-CoV-2 is associated with an increased risk of cardiovascular complications, especially thromboembolic complications. Low-molecular-weight-heparin presents a basic form of prophylaxis against thromboembolic complications in individuals who are ill with COVID-19. Controversy still exists regarding the optimal dose of LMWH depending on disease severity, this problem requires further randomised trials.
Keywords
thromboprophylaxis, Covid-19 thrombosis
About this articleTitle
Thromboprophylaxis in patients with Covid-19
Journal
Issue
Article type
Review paper
Pages
138-143
Published online
2022-01-28
Page views
4414
Article views/downloads
243
DOI
10.5603/AA.2021.0016
Bibliographic record
Acta Angiologica 2021;27(4):138-143.
Keywords
thromboprophylaxis
Covid-19 thrombosis